CCA
RIGL icon

Carrera Capital Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Carrera Capital Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,299
Closed -$942K – 163
2025
Q2 		$942K Buy
+50,299
New +$954K 0.19% 66

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carrera Capital Advisors's RIGL Position: Q3 2025 in Review

Carrera Capital Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2025, closing a stake of 50,299 shares — an estimated $942K sold.

Carrera Capital Advisors first reported a position in RIGL in Q2 2025 and held it in 1 quarter. The position peaked at $942K in Q2 2025. 169 funds tracked by Wall St. Rank hold RIGL as of Q3 2025.

  • Carrera Capital Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Carrera Capital Advisors sold 50,299 Rigel Pharmaceuticals shares in Q3 2025, an estimated $942K.
  • Carrera Capital Advisors first reported a position in Rigel Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Carrera Capital Advisors's Rigel Pharmaceuticals position peaked at $942K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2025.

Based on Carrera Capital Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.